Home›Ombitasvirparitaprevirritonavir›Ombitasvirparitaprevirritonavir + Norethindrone Acetateethinyl Estradiol

Does Ombitasvirparitaprevirritonavir Interact with Norethindrone Acetateethinyl Estradiol?

Ombitasvirparitaprevirritonavir and Norethindrone Acetateethinyl Estradiol have a contraindicated drug interaction according to U.S. FDA drug labeling data. Coadministration is contraindicated due to potential for ALT elevations and risk of liver enzyme elevation. The mechanism involves hepatic enzyme elevation. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Contraindicated
Norethindrone Acetateethinyl Estradiol Class
Estrogen
Management
Do not take together
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Ombitasvirparitaprevirritonavir and Norethindrone Acetateethinyl Estradiol occurs because hepatic enzyme elevation. Clinically, this means coadministration is contraindicated due to potential for alt elevations and risk of liver enzyme elevation. Because of the severity of this interaction, these medications are contraindicated — meaning they should not be taken together under any circumstances. If you are currently taking both, contact your healthcare provider immediately to discuss alternatives.

What To Tell Your Doctor or Pharmacist

If you are taking Ombitasvirparitaprevirritonavir and your doctor is considering prescribing Norethindrone Acetateethinyl Estradiol (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask about alternative medications that do not interact with your current regimen
  • Ask how frequently you should be monitored while these are co-prescribed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Ombitasvirparitaprevirritonavir+💊 Norethindrone Acetateethinyl Estradiol(Femlyv)

Severity & Interaction Details

⛔
contraindicated
Avoid this combination
FDA labeling lists this pair as contraindicated. The risk outweighs the benefit in nearly all cases.
Severity scale
MinorContra
On record
Yes
Drug A class
—
Drug B class
Estrogen
Source
NLP:norethindrone acetate and ethinyl estradiol

What this means in plain English

Coadministration is contraindicated due to potential for ALT elevations and risk of liver enzyme elevation.

About Ombitasvirparitaprevirritonavir and Norethindrone Acetateethinyl Estradiol

Norethindrone Acetateethinyl Estradiol is an Estrogen. Norethindrone Acetateethinyl Estradiol is also sold under the brand name Femlyv. Norethindrone Acetateethinyl Estradiol is taken by mouth. Norethindrone Acetateethinyl Estradiol additionally carries an FDA boxed warning, the FDA's strongest safety alert.

What the FDA label says

"Hepatic enzyme elevation"

📖 Source: NLP:norethindrone acetate and ethinyl estradiol

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Ombitasvirparitaprevirritonavir and Norethindrone Acetateethinyl Estradiol against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
Data integrity: Every interaction shown is extracted directly from official U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NIH) — no interactions are invented, inferred, or manually edited. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.